CYTOKINETICS INC — Director's Dealing 2020

Dec 18, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CYTOKINETICS INC (CYTK)
CIK: 0001061983
Period of Report: 2020-12-15

Reporting Person: Cragg David (SVP Human Resources)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-12-15	Common Stock	M	7423	$9.42	Acquired	147639	Direct
2020-12-15	Common Stock	F	4745	$21.0	Disposed	142894	Direct
2020-12-15	Common Stock	M	9243	$9.42	Acquired	152137	Direct
2020-12-15	Common Stock	F	5908	$21.0	Disposed	146229	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-12-15	Incentive Stock Option (right to buy)	$9.42	C	7423	Disposed	2021-02-28	Common Stock (7423)	Direct
2020-12-15	Non-Qualified Stock Option (right to buy)	$9.42	C	7423	Acquired	2021-02-28	Common Stock (7423)	Direct
2020-12-15	Non-Qualified Stock Option (right to buy)	$9.42	M	7423	Disposed	2021-02-28	Common Stock (7423)	Direct
2020-12-15	Non-Qualified Stock Option (right to buy)	$9.42	M	9243	Disposed	2021-02-28	Common Stock (9243)	Direct

Footnotes

F1: Includes up to 13,132 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan.

F2: Transaction represents a "net exercise" of 9,243 outstanding non-qualified stock options granted on 2/28/2011 and 7,423 outstanding non-qualified stock options that result from the conversion on 12/15/20 of incentive stock options granted on 2/28/2011. The Reporting Person received 6,013 shares of Common Stock on the net exercise of a stock options to purchase an aggregate of 16,666 shares of Common Stock, with a remaining payable by Reporting Person to the Issuer of $17.45. The Issuer withheld 10,653 shares of Common Stock underlying the stock options for payment of the exercise price and tax withholding using a stock price on 12/15/20 of $21.00. In addition to the withholding of 10,653 shares of Common Stock, the Reporting Person will pay $17.45 in cash to the Issuer for the remainder of his exercise price and tax liability.

F3: Incentive stock options granted on 2/28/2011 to purchase 7,423 shares at an exercise price of $9.42 per share converted to non-qualified stock options to purchase 7,423 shares at an exercise price of $9.42 per share as a result of a modification to the original grant to permit a "net exercise" of the stock options. Conversion transaction is permitted pursuant to the Issuer's Amended and Restated 2004 Equity Incentive Plan and the prior resolution of the Issuer's Compensation and Talent Committee of the Board of Directors.

F4: Number of derivative securities beneficially owned following reported transaction is zero (0). The 1 security that is reported is the result of rounding of shares attributable to Issuer?s reverse stock split that occurred on 6/25/2013.